๐ฐ Looking Statement News
Page 10 - Looking Statement News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Looking Statement. Real-time updates on events, politics, business and more.
January 18, 2024
Powerful new people development capabilities to equip Dayforce™ customers with optimized training and development programs for the extended workforceTORONTO and MINNEAPOLIS, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Ceridian (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, today announced it has entered into a definitive agreement to acquire eloomi, a leading learning experience platform software provider based in Copenhagen, Denmark, and Orlando, Florida. Th...
January 18, 2024
Real American Announces Appointment of Officers and Directors
January 18, 2024
Real American Announces Appointment of Officers and Directors
January 17, 2024
LOS ANGELES, Jan. 17, 2024 -- Big Screen Entertainment Group continues to strengthen its collaboration with renowned screenwriter Mark Cramer by acquiring the rights to his latest scripts for two...
January 16, 2024
Corporate Leadership Transition Brings Strong Revenue Forecast for 2024 GREER, S.C., Jan. 16, 2024 /PRNewswire/ -- Loud Beverage Group, Inc. , a holding company specializing in the distribution of a...
January 16, 2024
Loud Beverage Group, Inc. , a holding company specializing in the distribution of a diverse range of high quality, innovative, and in-demand products, is pleased to announce its successful acquisition of Surge Distribution Company, LLC, a South...
January 13, 2024
12.01.2024 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merckโs anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of ...
January 12, 2024
KEYTRUDA is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients Approval marks third FDA-approved indication for KEYTRUDA in cervical cancer and...
January 10, 2024
Mynaric Reports on Key Performance Indicators for 2023
January 8, 2024
Acquisition includes HPN328, an investigational delta-like ligand 3 targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors ...